Division of Pulmonology and Critical Care, Allegheny Health Network, Pittsburg, PA 15212, USA.
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66103, USA.
Viruses. 2023 Feb 22;15(3):600. doi: 10.3390/v15030600.
Heart failure exacerbations impart significant morbidity and mortality, however, large- scale studies assessing outcomes in the setting of concurrent coronavirus disease-19 (COVID-19) are limited. We utilized National Inpatient Sample (NIS) database to compare clinical outcomes in patients admitted with acute congestive heart failure exacerbation (CHF) with and without COVID-19 infection. A total of 2,101,980 patients (Acute CHF without COVID-19 ( = 2,026,765 (96.4%) and acute CHF with COVID-19 ( = 75,215, 3.6%)) were identified. Multivariate logistic regression analysis was utilized to compared outcomes and were adjusted for age, sex, race, income level, insurance status, discharge quarter, Elixhauser co-morbidities, hospital location, teaching status and bed size. Patients with acute CHF and COVID-19 had higher in-hospital mortality compared to patients with acute CHF alone (25.78% vs. 5.47%, adjust OR (aOR) 6.3 (95% CI 6.05-6.62, < 0.001)) and higher rates of vasopressor use (4.87% vs. 2.54%, aOR 2.06 (95% CI 1.86-2.27, < 0.001), mechanical ventilation (31.26% vs. 17.14%, aOR 2.3 (95% CI 2.25-2.44, < 0.001)), sudden cardiac arrest (5.73% vs. 2.88%, aOR 1.95 (95% CI 1.79-2.12, < 0.001)), and acute kidney injury requiring hemodialysis (5.56% vs. 2.94%, aOR 1.92 (95% CI 1.77-2.09, < 0.001)). Moreover, patients with heart failure with reduced ejection fraction had higher rates of in-hospital mortality (26.87% vs. 24.5%, adjusted OR 1.26 (95% CI 1.16-1.36, < 0.001)) with increased incidence of vasopressor use, sudden cardiac arrest, and cardiogenic shock as compared to patients with heart failure with preserved ejection fraction. Furthermore, elderly patients and patients with African-American and Hispanic descents had higher in-hospital mortality. Acute CHF with COVID-19 is associated with higher in-hospital mortality, vasopressor use, mechanical ventilation, and end organ dysfunction such as kidney failure and cardiac arrest.
心力衰竭恶化会导致显著的发病率和死亡率,但评估同时患有冠状病毒病 2019(COVID-19)患者结局的大规模研究有限。我们利用国家住院患者样本(NIS)数据库比较了急性充血性心力衰竭恶化(CHF)患者中伴有和不伴有 COVID-19 感染的临床结局。共纳入 2101980 例患者(急性 CHF 无 COVID-19(=2026765(96.4%)和急性 CHF 伴 COVID-19(=75215,3.6%))。采用多变量逻辑回归分析比较了结局,并根据年龄、性别、种族、收入水平、保险状况、出院季度、Elixhauser 合并症、医院位置、教学状态和床位大小进行了调整。与单纯急性 CHF 患者相比,急性 CHF 合并 COVID-19 患者的院内死亡率更高(25.78% vs. 5.47%,调整后的比值比[aOR]6.3(95%CI 6.05-6.62,<0.001)),并且更常使用血管加压药(4.87% vs. 2.54%,aOR 2.06(95%CI 1.86-2.27,<0.001))、机械通气(31.26% vs. 17.14%,aOR 2.3(95%CI 2.25-2.44,<0.001))、心搏骤停(5.73% vs. 2.88%,aOR 1.95(95%CI 1.79-2.12,<0.001))和需要血液透析的急性肾损伤(5.56% vs. 2.94%,aOR 1.92(95%CI 1.77-2.09,<0.001))。此外,射血分数降低的心力衰竭患者的院内死亡率更高(26.87% vs. 24.5%,调整后的比值比[aOR]1.26(95%CI 1.16-1.36,<0.001)),并且与射血分数保留的心力衰竭患者相比,使用血管加压药、心搏骤停和心源性休克的发生率更高。此外,老年患者和非裔美国人和西班牙裔患者的院内死亡率更高。急性 CHF 合并 COVID-19 与更高的院内死亡率、血管加压药使用、机械通气以及终末器官功能障碍(如肾衰竭和心搏骤停)相关。